The long-range objectives of this project are to clarify the mechanisms by which human cells maintain the genetic integrity of their DNA in the face of cytotoxic, mutagenic or carcinogenic insults. These goals are being approached through biochemical studies to identify and characterize the enzymes and reactions involved in repair of alkylation or radiation damage of DNA. The experiments are designed to answer questions about the critical initial steps of repair that involve recognition of a lesion or class of lesions by endonucleases, N-glycosylase or alkyltransferases. The endonuclease specific for UV- or -irradiated or oxidized DNA will be purified further from human lymphoblasts and attempts will be made to establish unequivocally that it comprises a combination of N-glycosylase and AP-endonuclease activities. The identity of the damaged bases recognized by this activity will be determined rigorously by derivitization of reaction products, HPLC and DNA-sequencing methods. The highly purified human DNA glycosylase specific for N-alkylpurines in DNA will be investigated for activity against O-alkylated pyrimidines, while the O6-alkylguanine-DNA alkyltransferase, purified 300-fold from human lymphoblasts, will be purified further and tested for activity against O-alkylated pyrimidines. A new endeavor concerns enzymes for repair of DNA interstrand cross-links induced by antineoplastic bifunctional alkylating agents. The mechanism(s) for O6-alkyltransferase-mediated repair of cross-link presursors induced by chloroethylnitrosoureas will be investigated. Preliminary studies indicating that the sensitivity of human rhabdomyosarcoma xenografts to the antineoplastic nitrosoureas relates to levels of transferase will be extended to other human tumor xenografts. Knowledge gained from the proposed research should contribute to an understanding of certain pathologic changes such as cancer and aging, or help explain variations in chemotherapeutic and radiotherapeutic responses of different cells. It may ultimately suggest approaches for predicting cellular sensitivity or interfering with the agents' biological effects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA014799-11
Application #
3164012
Study Section
Chemical Pathology Study Section (CPA)
Project Start
1977-08-01
Project End
1990-04-30
Budget Start
1985-05-01
Budget End
1986-04-30
Support Year
11
Fiscal Year
1985
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Danam, Rebecca P; Howell, Sherie R; Brent, Thomas P et al. (2005) Epigenetic regulation of O6-methylguanine-DNA methyltransferase gene expression by histone acetylation and methyl-CpG binding proteins. Mol Cancer Ther 4:61-9
Penketh, P G; Shyam, K; Baumann, R P et al. (2004) 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): I. Direct inhibition of O6-alkylguanine-DNA alkyltransferase (AGT) by electrophilic species generated by decomposition. Cancer Chemother Pharmacol 53:279-87
Baumann, R P; Shyam, K; Penketh, P G et al. (2004) 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): II. Role of O6-alkylguanine-DNA alkyltransferase in cytotoxicity. Cancer Chemother Pharmacol 53:288-95
Petak, I; Danam, R P; Tillman, D M et al. (2003) Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma. Cell Death Differ 10:211-7
Schwartzberg, Lee S; Petak, Istvan; Stewart, Clinton et al. (2002) Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin. Clin Cancer Res 8:2488-98
Danam, R P; Howell, S R; Remack, J S et al. (2001) Heterogeneous methylation of the O(6)-methylguanine-DNA methyltransferase promoter in immortalized IMR90 cell lines. Int J Oncol 18:1187-93
Sawai, N; Zhou, S; Vanin, E F et al. (2001) Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector. Mol Ther 3:78-87
Middlemas, D S; Stewart, C F; Kirstein, M N et al. (2000) Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res 6:998-1007
Houghton, P J; Stewart, C F; Cheshire, P J et al. (2000) Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res 6:4110-8
Herfarth, K K; Brent, T P; Danam, R P et al. (1999) A specific CpG methylation pattern of the MGMT promoter region associated with reduced MGMT expression in primary colorectal cancers. Mol Carcinog 24:90-8

Showing the most recent 10 out of 48 publications